Levodopa/Carbidopa/Entacaponă Teva (Carbidopa, Entacapone, Levodopa)

Levodopa is a dopamine precursor that crosses the blood‑brain barrier and is converted to dopamine. Carbidopa blocks peripheral decarboxylation of levodopa, allowing more of the drug to reach the brain. Entacapone inhibits the COMT enzyme, slowing levodopa breakdown and prolonging its therapeutic effect.

The dosage of Levodopa/Carbidopa/Entacaponă is individualized. A qualified prescriber determines the appropriate strength, frequency and total daily dose based on the patient’s disease stage, response to therapy and tolerability. Patients should follow the prescribing information provided by their healthcare professional.

Safety data for Levodopa/Carbidopa/Entacaponă in pregnancy and lactation are limited. The product is classified as having an unknown pregnancy category, and it should only be used if the potential benefit justifies any possible risk to the fetus or infant. Consultation with a specialist is essential.

To place an order, visit the product page on gnhindia.com, submit an enquiry with the required quantity, and provide institutional or trade credentials. GNH India’s team will verify the information, then respond with pricing, availability, shipping details and any necessary import documentation.

Compared with levodopa alone, the addition of carbidopa reduces peripheral side effects and increases central availability, while entacapone further extends levodopa’s half‑life. This triple combination often provides smoother symptom control and fewer motor fluctuations than single‑component regimens.

Levodopa/Carbidopa/Entacaponă tablets should be stored at ambient temperature, below 25 °C, in the original blister pack. Keep the container tightly closed, protect from moisture and direct sunlight, and discard any tablets that appear discolored or damaged.

The medication is taken orally, usually with a glass of water. It can be taken with or without food, but consistent timing relative to meals helps maintain stable plasma levels. Patients should swallow the tablets whole and avoid crushing or chewing them unless directed otherwise.

Serious risks include dyskinesia (involuntary movements), hallucinations or psychosis, severe orthostatic hypotension, and rare cases of neuroleptic malignant syndrome. Prompt medical attention is required if any of these symptoms develop, as they may indicate the need for dose adjustment or discontinuation.

Patients with known hypersensitivity to levodopa, carbidopa, entacapone or any excipients should avoid this product. It is also contraindicated in individuals taking non‑selective MAO inhibitors or those with a history of malignant neuroleptic syndrome. Clinicians must evaluate each patient’s medical history before prescribing.